Adrenoleukodystrophy

Results: 31



#Item
1The company is located in the Parc TecnoCampus Mataró-Maresme  ”la Caixa” leads a 1.6 million Euro round in Minoryx • Minoryx is dedicated to treating rare or orphan diseases, focusing on those derived from congen

The company is located in the Parc TecnoCampus Mataró-Maresme ”la Caixa” leads a 1.6 million Euro round in Minoryx • Minoryx is dedicated to treating rare or orphan diseases, focusing on those derived from congen

Add to Reading List

Source URL: www.caixacapitalrisc.es

Language: English - Date: 2015-01-23 06:13:25
2Rare Disease DayJoin MassBio, VHL Alliance, member companies, patient groups, patients and legislators to recognize Rare Disease Day. Friday, February 28th 11 a.m.

Rare Disease DayJoin MassBio, VHL Alliance, member companies, patient groups, patients and legislators to recognize Rare Disease Day. Friday, February 28th 11 a.m.

Add to Reading List

Source URL: www.massbio.org

Language: English - Date: 2014-03-12 17:41:27
3

PDF Document

Add to Reading List

Source URL: www.hrsa.gov

Language: English
4HK J Paediatr (new series) 2005;10:[removed]MCQs Instruction: 1. Please use pencil to shade the box for the correct answer (see loose leaf page). 2. Send back the answer sheet to the Hong Kong College of Paediatricians f

HK J Paediatr (new series) 2005;10:[removed]MCQs Instruction: 1. Please use pencil to shade the box for the correct answer (see loose leaf page). 2. Send back the answer sheet to the Hong Kong College of Paediatricians f

Add to Reading List

Source URL: www.fmshk.com.hk

Language: English - Date: 2006-06-28 04:23:07
5JUNE[removed]NASDAQ: BLUE Transforming the Lives of Patients

JUNE[removed]NASDAQ: BLUE Transforming the Lives of Patients

Add to Reading List

Source URL: www.bluebirdbio.com

Language: English - Date: 2014-12-05 11:30:09
6PROTOCOL ALD-102 AN OPEN LABEL, NON-RANDOMIZED, SINGLE DOSE, MULTI-CENTER PHASE 2/3 STUDY OF THE SAFETY AND EFFICACY OF LENTI-D MODIFIED AUTOLOGOUS STEM CELLS (LENTI-D DRUG PRODUCT) FOR THE TREATMENT OF SUBJECTS WITH CHI

PROTOCOL ALD-102 AN OPEN LABEL, NON-RANDOMIZED, SINGLE DOSE, MULTI-CENTER PHASE 2/3 STUDY OF THE SAFETY AND EFFICACY OF LENTI-D MODIFIED AUTOLOGOUS STEM CELLS (LENTI-D DRUG PRODUCT) FOR THE TREATMENT OF SUBJECTS WITH CHI

Add to Reading List

Source URL: osp.od.nih.gov

Language: English - Date: 2013-12-31 13:09:44
7INSIDE  » Board Elects New Trustees » Martin Hetzer Receives Scholar Award » One on One with Bob Lizarraga Where cures begin.

INSIDE » Board Elects New Trustees » Martin Hetzer Receives Scholar Award » One on One with Bob Lizarraga Where cures begin.

Add to Reading List

Source URL: www.salk.edu

Language: English - Date: 2012-04-12 21:07:44
8X-linked Adrenoleukodystrophy (ALD) Fred Lorey, Ph.D Genetic Disease Screening Program, California Department of Public Health

X-linked Adrenoleukodystrophy (ALD) Fred Lorey, Ph.D Genetic Disease Screening Program, California Department of Public Health

Add to Reading List

Source URL: www.hrsa.gov

Language: English - Date: 2014-12-04 01:13:43
9Paula K. Brazeal, President  The United Leukodystrophy Foundation was founded in 1982 with a mission dedicated to helping children and adults who have leukodystrophy and assisting the family members, professionals, and s

Paula K. Brazeal, President The United Leukodystrophy Foundation was founded in 1982 with a mission dedicated to helping children and adults who have leukodystrophy and assisting the family members, professionals, and s

Add to Reading List

Source URL: www.hrsa.gov

Language: English - Date: 2014-12-04 01:12:59
10Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children Summary of 28th Meeting September 13-14, 2012 Washington, DC

Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children Summary of 28th Meeting September 13-14, 2012 Washington, DC

Add to Reading List

Source URL: www.hrsa.gov

Language: English - Date: 2014-12-04 01:13:59